A comparative sub-cohort analysis, however, revealed that patients with a TMT of 7.0 mm and more were mostly male (as already analyzed before), received GTR as well as adjuvant chemotherapy with temozolomide more often, and had corresponding tumor samples that revealed a methylated MGMT promoter more frequently (Table 3). Here, MGMT is linked to neoplasm.